Aadi bioscience announces financial results for the second quarter 2024 and provides corporate update

Fyarro® sales of $6.2 million for q2 2024, a 15% quarter over quarter sales growth interim analysis of two-thirds of fully enrolled precision1 trial planned for q3 2024 conference call to be held today at 8:30 am edt los angeles , aug. 7, 2024 /prnewswire/ -- aadi bioscience, inc. (nasdaq: aadi), a commercial-stage, precision oncology company focused on developing and commercializing therapies for cancers with alterations in the mtor pathway, today announced financial results for the second quarter ended june 30, 2024, and highlighted recent corporate progress. "the second quarter saw quarter over quarter sales growth for fyarro, as anticipated, and an increase in demand across both new and existing accounts, including from major oncology centers.
AADI Ratings Summary
AADI Quant Ranking